New digital course takes a population-level approach to curbing prescription drug abuse WASHINGTON DC (November 16, 2017) – The Association for Accessible Medicines (AAM) today announced a
Continued from Part 2… So maybe the penalty is unfair, but what’s going to happen other than some drug companies earning a little less money?
WASHINGTON DC (NOVEMBER 6, 2017) – Brett Michelin and Ashlie Van Meter are joining the Association for Accessible Medicines’ (AAM) State Government Affairs team as Director
Generic medicines represent nearly 90 percent of all prescriptions written in the United States, but only 26 percent of the costs, saving patients and payers
AAM commends the Supreme Court for upholding the constitutionality of the Inter Partes Review (IPR) process. This is a win for patients who depend on
For more than four decades, U.S. Patent and Trademark Office (PTO) review of issued patents has been considered a vital component of a healthy patent
On October 17, 2017, the Senate Health, Education, Labor and Pensions Committee, under the leadership of Senators Lamar Alexander (R-TN) and Patty Murray (D-WA), convened
Bill fails to recognize business model of generic industry. WASHINGTON, DC (October 10, 2017) – State laws that burden manufacturers of low-cost generic and biosimilar medicines harm
WASHINGTON, DC (September 29, 2017) – The Association for Accessible Medicines (AAM) is disappointed with the district court’s decision not to enjoin Maryland’s price gouging
While the pills you receive at the pharmacy counter may look slightly different from the brand, generic medicines work the same as costlier brand-name products.
WASHINGTON, DC (September 19, 2017) — Today, the Association for Accessible Medicines (AAM) and its Biosimilars Council released an analysis finding that if the Centers
WASHINGTON, DC (September 19, 2017) – Access to safe, affordable generic medication is a critical lifeline to millions of patients, with individuals and families receiving coverage
